Risk of Developing Hypertension in Atopic Dermatitis Patients Receiving Long-term and Low-dose Cyclosporine: A Nationwide Population-based Cohort Study
- Author:
Yu Ri WOO
1
;
Arum CHOI
;
Seo Won SONG
;
Suyeun KIM
;
Sang Wook SON
;
Sang Hyun CHO
;
Sukil KIM
;
Jung Eun KIM
Author Information
- Publication Type:Original Article
- From:Annals of Dermatology 2024;36(2):112-119
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Cyclosporine (CS) is a first-line immunosuppressive agent used to manage moderate to severe atopic dermatitis (AD). To date, the risk of developing hypertension associated with the long-term use of low-dose CS in AD patients is understudied.
Objective:To determine the cumulative dose-dependent effect of CS on the risk of developing hypertension in patients with AD.
Methods:A nationwide population-based retrospective cohort with 1,844,009 AD patients was built from the Korean National Health Insurance System database from 2005 to 2009.A Cox proportional-hazard regression analysis was performed according to patients’ CS treatment history adjusted for potential confounders.
Results:Current use of CS was associated with an increased risk of developing hypertension (adjusted hazard ratio, 4.442; 95% confidence interval, 3.761–5.247). Among the current CS users, a higher cumulative dose of CS (≥39,725 mg) or longer cumulative use of CS (≥182 days), was significantly associated with an increased risk of developing hypertension.
Conclusion:The incidence of CS-associated hypertension is very low when using low-dose treatment regimens for AD. However, the current use or a high cumulative dose of CS for treating patients with AD increases the risk of developing hypertension. Precaution is needed when prescribing CS for long-term treatment of AD.
